株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

持続的腎機能代替療法 (CRRT) の世界市場予測 2022年:SCUF・CVVH・CVVHD・CVVHDF

Continuous Renal Replacement Therapy (CRRT) Market by Product (Systems, Disposables (Hemofilters & Bloodlines), & Dialysate), Modality (SCUF, CVVH, CVVHD, CVVHDF), Adoption & Procedures, and Region - Forecast to 2022

発行 MarketsandMarkets 商品コード 344289
出版日 ページ情報 英文 191 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.89円で換算しております。
Back to Top
持続的腎機能代替療法 (CRRT) の世界市場予測 2022年:SCUF・CVVH・CVVHD・CVVHDF Continuous Renal Replacement Therapy (CRRT) Market by Product (Systems, Disposables (Hemofilters & Bloodlines), & Dialysate), Modality (SCUF, CVVH, CVVHD, CVVHDF), Adoption & Procedures, and Region - Forecast to 2022
出版日: 2017年07月20日 ページ情報: 英文 191 Pages
概要

世界の持続的腎機能代替療法 (CRRT:Continuous Renal Replacement Therapy) の市場は、2017年の10億9,000万米ドルから、2022年までに15億3,000万米ドルへ、7.0%のCAGR (年間複合成長率) で成長すると予測されています。急性腎損傷の発生率の増加、ICU患者数の増加、敗血症の発生率の増加、および技術進歩は、CRRT市場の成長を抑制する要因となっています。しかし、CRRTの処置費用が高額であること、および北米におけるCRRTの規制ガイドラインが厳しいことは、同市場の成長を抑制する見込みです。

当レポートでは、世界の持続的腎機能代替療法 (CRRT:Continuous Renal Replacement Therapy) の市場を調査し、CRRTの概要、モダリティおよび構成製品の種類と概要、市場成長への各種影響因子、市場機会、市場の潜在性に関する分析、各地域の法規制環境、地域別のCRRTの利用動向、製品区分・モダリティ別の市場規模の推移と予測、地域および主要国における動向、競合環境と市場シェア、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • CRRT:市場概要
  • 世界のCRRT市場:製品タイプ別
  • CRRT市場:モダリティ・地域別
  • 地域概要:CRRT市場

第5章 市場概要

  • イントロダクション
  • 市場ダイナミクス
    • 市場推進要因
    • 市場抑制要因
    • 市場機会
    • 課題

第6章 産業分析

  • イントロダクション
  • 償還シナリオ
    • 北米
    • 欧州
    • アジア太平洋
    • 日本
    • その他
  • 法規制環境
    • 北米
    • 欧州
    • アジア太平洋
    • その他
    • 産業動向
  • ポーターのファイブフォース分析
  • 価格・コスト分析
  • 戦略的提言

第7章 CRRTの導入:地域別

  • イントロダクション
  • CRRTの活用動向:地域別
  • CRRT患者数:地域別

第8章 CRRT市場:製品別

  • イントロダクション
    • 透析液・置換液
    • 使い捨て品
      • 血液濾過器
      • チューブセット
      • その他
    • システム

第9章 CRRT市場:モダリティ別

  • イントロダクション
  • 持続的静静脈血液濾過 (CVVH:CONTINUOUS VENOVENOUS HEMOFILTRATION)
  • 持続的静静脈血液濾過透析 (CVVHDF:CONTINUOUS VENOVENOUS HEMODIAFILTRATION)
  • 持続的静静脈血液透析 (CVVHD:CONTINUOUS VENOVENOUS HEMODIALYSIS)
  • SCUF (SLOW-CONTINUOUS ULTRAFILTRATION)

第10章 地域別市場

  • イントロダクション
  • 欧州
  • 北米
  • アジア太平洋
  • その他の地域 (RoW)

第11章 競合環境

  • イントロダクション
  • 製品ポートフォリオの長所
  • 優れた事業戦略
  • 競合の強度

第12章 企業プロファイル

  • BAXTER INTERNATIONAL INC.
  • FRESENIUS MEDICAL CARE AG & CO. KGAA
  • 日機装
  • NXSTAGE MEDICAL, INC.
  • B. BRAUN MELSUNGEN AG
  • 旭化成メディカル (旭化成メディカル子会社)
  • BELLCO S.R.L.
  • 東レ・メディカル
  • INFOMED SA
  • MEDICA S.P.A
  • MEDICAL COMPONENTS, INC.
  • MEDITES PHARMA SPOL. S.R.O.
  • MEDTRONIC PLC
  • SWS HEMODIALYSIS CARE CO. LTD.
  • NINGBO TIANYI MEDICAL APPLIANCE CO., LTD.

第13章 付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: MD 3842

The global CRRT market is projected to reach USD 1.53 billion by 2022 from USD 1.09 billion in 2017, at a CAGR of 7.0%. Increasing global incidence of acute kidney injury, growing number of ICU patients, increasing incidence of sepsis, and tehcnologcal advancements are some of the factors driving the growth of the CRRT market. However, high procedural cost of CRRT and stringent regulatory guidelines for CRRT in North America are expected to hinder market growth.

"Hemofilters to form the largest segment of CRRT disposables as of 2017"

On the basis of product, CRRT disposables segment is further sub-segmented to the bloodline sets, hemofilters, and other disposables (such as vascular access catheters and CRRT accessories, including drainage bags, ancillaries, stop cocks, syringes, and priming solutions). The hemofilters segment is estimated to account for the largest share of the disposables market due to the development of novel hemofilters and their increasing use in CRRT procedures.

"Continuous Venovenous Hemofiltration (CVVH) modality segment expected to be the largest segment during 2017-2022"

Based on modality, the CRRT market is segmented into slow continuous ultrafiltration (SCUF), continuous venovenous hemofiltration (CVVH), continuous venovenous hemodialysis (CVVHD), and continuous venovenous hemodiafiltration (CVVHDF). The The CVVH modality is estimated to account for the largest share of the global CRRT market owing to the wide adoption of this modality among healthcare providers.

"Asia-Pacific is expected to register the highest growth rate in the CRRT market"

Geographically, the CRRT market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. Asia-Pacific is expected to register the highest growth rate during the forecast period, owing to the large acute kidney injury patient population, high utilization of CRRT in Australia and Japan, and improving healthcare infrastructure across Asian countries.

Breakdown of supply-side primary interviews:

  • By Company Type - Tier 1 - 40%, Tier 2 - 25%, and Tier 3 - 35%
  • By Designation - C level - 26%, Director level - 30%, and Others - 44%
  • By Region - North America - 34%, Europe - 26%, APAC - 23%, and RoW - 17%

The major players in the market are Baxter International Inc. (U.S.), Fresenius Medical Care AG & Co. KGaA (Germany), Nikkiso Co., Ltd. (Japan), B. Braun Melsungen AG (Germany), Bellco S.r.l. (Italy), NxStage Medical, Inc. (U.S.), Asahi Kasei Corporation (Japan), Infomed SA (Switzerland), and Medica S.p.A. (Italy), and Toray Medical Co., Ltd. (Japan).

Research Coverage:

This report studies the CRRT market based on product and modality. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and prospects in the total market. The report forecasts the revenue of the market segments with respect to four main regions.

Reasons to Buy the Report:

From an insights perspective, this research report has focused on various levels of analysis-industry trends, market share analysis of top ten players, and company profiles, which together comprise and discuss basic views on the competitive landscape, emerging and high-growth segments of the CRRT market, and high-growth regions and countries and their respective drivers, restraints, challenges, and opportunities.

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn help firms garner greater market shares. Firms purchasing the report could use any one or a combination of the recommended strategies for strengthening their market shares.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. GEOGRAPHIC SCOPE
    • 1.3.3. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH APPROACH
  • 2.2. SECONDARY AND PRIMARY RESEARCH METHODOLOGY
    • 2.2.1. SECONDARY RESEARCH
      • 2.2.1.1. Key data from secondary sources
    • 2.2.2. PRIMARY RESEARCH
      • 2.2.2.1. Key data from primary sources
      • 2.2.2.2. Key industry insights
  • 2.3. MARKET SIZE ESTIMATION METHODOLOGY
  • 2.4. MARKET DATA VALIDATION AND TRIANGULATION
  • 2.5. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. CRRT: MARKET OVERVIEW (2017)
  • 4.2. GLOBAL CRRT MARKET, BY PRODUCT, 2017 VS. 2022
  • 4.3. CRRT MARKET, BY MODALITY AND REGION (2017)
  • 4.4. GEOGRAPHIC SNAPSHOT: CRRT MARKET (2017)

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. DRIVERS
      • 5.2.1.1. Increasing global incidence of AKI
      • 5.2.1.2. Growing number of ICU patients
      • 5.2.1.3. Clinical advantages of CRRT over intermittent blood purification techniques
      • 5.2.1.4. Technological advancements and new product launches
      • 5.2.1.5. Increasing incidence of sepsis
      • 5.2.1.6. Growing prevalence of diabetes and hypertension
    • 5.2.2. RESTRAINTS
      • 5.2.2.1. High procedural cost of CRRT
      • 5.2.2.2. Stringent regulatory guidelines for CRRT in North America
    • 5.2.3. OPPORTUNITIES
      • 5.2.3.1. Emerging markets
      • 5.2.3.2. Increasing applications of CRRT
        • 5.2.3.2.1. Evolution of CRRT from a simple renal replacement treatment to a multi-organ support therapy (MOST)
        • 5.2.3.2.2. Progression of CRRT from adaptive renal devices to multipurpose treatment machines
      • 5.2.3.3. Ongoing research to establish the safety and efficacy profile of CRRT
      • 5.2.3.4. Development of a CRRT system for pediatric patients
        • 5.2.3.4.1. The CARPEDIEM project
      • 5.2.3.5. Untapped market growth opportunities in North America
    • 5.2.4. CHALLENGES
      • 5.2.4.1. High complexity of the therapy
        • 5.2.4.1.1. Lack of standard treatment guidelines in developing countries
        • 5.2.4.1.2. Complications associated with CRRT
      • 5.2.4.2. Shortage of trained ICU nurses in developed countries
      • 5.2.4.3. Poor reimbursement scenario in developing countries
      • 5.2.4.4. Lack of awareness about the benefits of CRRT

6. INDUSTRY INSIGHTS

  • 6.1. INTRODUCTION
  • 6.2. REIMBURSEMENT SCENARIO
    • 6.2.1. NORTH AMERICA
    • 6.2.2. EUROPE
    • 6.2.3. ASIA-PACIFIC (EXCLUDING JAPAN)
    • 6.2.4. JAPAN
    • 6.2.5. REST OF THE WORLD
  • 6.3. REGULATORY LANDSCAPE
    • 6.3.1. NORTH AMERICA
    • 6.3.2. EUROPE
    • 6.3.3. ASIA-PACIFIC
    • 6.3.4. REST OF THE WORLD
    • 6.3.5. INDUSTRY TRENDS
      • 6.3.5.1. Training programs for the operation of CRRT devices
      • 6.3.5.2. Rising adoption of user-friendly CRRT machines
      • 6.3.5.3. Development of a CRRT system for pediatric patients
  • 6.4. PORTER'S FIVE FORCES ANALYSIS
    • 6.4.1. COMPETITIVE INTENSITY
    • 6.4.2. BARGAINING POWER OF BUYERS
    • 6.4.3. BARGAINING POWER OF SUPPLIERS
    • 6.4.4. THREAT OF SUBSTITUTES
    • 6.4.5. THREAT OF NEW ENTRANTS
  • 6.5. PRICING AND COST ANALYSIS
  • 6.6. STRATEGIC RECOMMENDATIONS
    • 6.6.1. DESIGN RECOMMENDATIONS
    • 6.6.2. KEY STRATEGIES FOR PLAYERS SEEKING TO ENTER THE CRRT MARKET

7. ADOPTION OF CONTINUOUS RENAL REPLACEMENT THERAPY, BY REGION

  • 7.1. INTRODUCTION
  • 7.2. UTILIZATION OF CRRT PROCEDURES, BY REGION
  • 7.3. NUMBER OF CRRT PATIENTS, BY REGION

8. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT

  • 8.1. INTRODUCTION
    • 8.1.1. DIALYSATES AND REPLACEMENT FLUIDS
    • 8.1.2. DISPOSABLES
      • 8.1.2.1. Hemofilters
      • 8.1.2.2. Bloodline sets (tubing sets)
      • 8.1.2.3. Other disposables
    • 8.1.3. SYSTEMS

9. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY

  • 9.1. INTRODUCTION
  • 9.2. CONTINUOUS VENOVENOUS HEMOFILTRATION (CVVH)
  • 9.3. CONTINUOUS VENOVENOUS HEMODIAFILTRATION (CVVHDF)
  • 9.4. CONTINUOUS VENOVENOUS HEMODIALYSIS (CVVHD)
  • 9.5. SLOW CONTINUOUS ULTRAFILTRATION (SCUF)

10. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY REGION

  • 10.1. INTRODUCTION
  • 10.2. EUROPE
    • 10.2.1. APPROVAL OF CRRT MACHINES FOR MULTIPLE APPLICATIONS
    • 10.2.2. INTENSIVIST PREFERENCE FOR CRRT FOR AKI TREATMENT
    • 10.2.3. PLAYERS FOCUS ON LEVERAGING GROWTH OPPORTUNITIES IN EUROPE
    • 10.2.4. GERMANY
      • 10.2.4.1. Rising focus of players on the German CRRT market
      • 10.2.4.2. Favorable reimbursement for CRRT
    • 10.2.5. U.K.
      • 10.2.5.1. Rising awareness about AKI in the U.K.
    • 10.2.6. FRANCE
      • 10.2.6.1. Significant number of ongoing clinical studies
    • 10.2.7. REST OF EUROPE
  • 10.3. NORTH AMERICA
    • 10.3.1. HIGH PREFERENCE FOR OTHER DIALYSIS MODALITIES
    • 10.3.2. REGULATORY POLICIES, A KEY HINDRANCE TO MARKET GROWTH
    • 10.3.3. U.S.
      • 10.3.3.1. Growth in AKI prevalence
      • 10.3.3.2. New product development to boost the demand for CRRT products
      • 10.3.3.3. Ongoing clinical trials to prove the safety and efficacy of CRRT products
      • 10.3.3.4. Shortage of registered nurses in ICU settings
    • 10.3.4. CANADA
      • 10.3.4.1. Rising AKI prevalence
      • 10.3.4.2. High cost of CRRT as compared to IHD
  • 10.4. ASIA-PACIFIC
    • 10.4.1. INCREASING NUMBER OF SEPSIS CASES IN INDIA
    • 10.4.2. STUDIES AND CLINICAL TRIALS TO ESTABLISH THE SAFETY AND EFFICACY PROFILE OF CRRT
    • 10.4.3. UNFAVORABLE REIMBURSEMENT SCENARIO
    • 10.4.4. JAPAN
      • 10.4.4.1. Increasing use of CRRT for non-renal indications
      • 10.4.4.2. Well-established healthcare system
      • 10.4.4.3. Large number of domestic manufacturers-a barrier to the entry of major players
    • 10.4.5. CHINA
      • 10.4.5.1. Rising incidence of AKI and ESRD in China
      • 10.4.5.2. Ongoing research studies
    • 10.4.6. INDIA
      • 10.4.6.1. Rising sepsis cases in India
      • 10.4.6.2. Increase in the number of dialysis patients
      • 10.4.6.3. Rising number of patients admitted to ICUs
      • 10.4.6.4. Unfavorable reimbursement scenario
      • 10.4.6.5. Lack of randomized trials and dearth of technical expertise
      • 10.4.6.6. Dearth of indigenous manufacturers for CRRT products in India
    • 10.4.7. REST OF ASIA-PACIFIC
      • 10.4.7.1. Taiwan, a lucrative market for CRRT players
  • 10.5. REST OF THE WORLD (ROW)
    • 10.5.1. LATIN AMERICA AND THE MIDDLE EAST
    • 10.5.2. NEW AMENDMENTS OPEN BRAZILIAN HEALTHCARE INDUSTRY TO FOREIGN INVESTMENT

11. COMPETITIVE LANDSCAPE

  • 11.1. INTRODUCTION
    • 11.1.1. VISIONARY LEADERS
    • 11.1.2. INNOVATORS
    • 11.1.3. DYNAMIC DIFFERENTIATORS
    • 11.1.4. EMERGING COMPANIES
  • 11.2. STRENGTH OF PRODUCT PORTFOLIO
  • 11.3. BUSINESS STRATEGY EXCELLENCE
  • 11.4. COMPETITIVE INTENSITY
    • 11.4.1. EVALUATION PARAMETERS AND SCORES
    • 11.4.2. SCORING METHODOLOGY
    • 11.4.3. COMPETITIVE INTENSITY SCORE, BY COMPANY
      • 11.4.3.1. Baxter International Inc.
      • 11.4.3.2. Fresenius Medical Care AG & Co. KGaA
      • 11.4.3.3. Nikkiso Co., Ltd.
      • 11.4.3.4. B. Braun Melsungen AG
      • 11.4.3.5. NxStage Medical, Inc.
    • 11.4.4. COMPETITIVE INTENSITY - MAPPING OF BAXTER INTERNATIONAL INC., FRESENIUS MEDICAL CARE AG & CO. KGAA, NIKKISO CO., LTD., B. BRAUN MELSUNGEN AG, AND NXSTAGE MEDICAL, INC.

Top 25 companies analyzed for this studies are - Baxter International Inc. (U.S.), Fresenius Medical Care AG & Co. KGaA (Germany), NxStage Medical, Inc. (U.S.), NIKKISO CO., LTD. (Japan), B. Braun Melsungen AG (Germany), Asahi Kasei Corporation (Japan), Bellco S.r.l. (Italy), Toray Medical Co., Ltd. (Japan), Infomed SA (Switzerland), Medica S.p.A. (Italy), Medical Components, Inc. (U.S.), Medites Pharma spol. s.r.o. (Czech Republic), Medtronic plc (Ireland), SWS Hemodialysis Care Co., Ltd. (China), Ningbo Tianyi Medical Devices Co., Ltd (China), CytoSorbents Corporation (U.S.), BIOMEDICA spol. s r.o. (Czech Republic), Anjue Medical Equipment Co., Ltd. (China), Jiangxi Sanxin Medtec Co., Ltd. (China), Proxima Medicare (India), Nipro Corporation (Japan), CytoPherx, Inc. (U.S.), Dialysis Solutions Inc. (U.S.), Kimal Electronics Ltd (U.K.), BL Lifesciences (India)

12. COMPANY PROFILES (Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, Recent Developments)*

  • 12.1. BAXTER INTERNATIONAL INC.
  • 12.2. FRESENIUS MEDICAL CARE AG & CO. KGAA
  • 12.3. NIKKISO CO., LTD.
  • 12.4. NXSTAGE MEDICAL, INC.
  • 12.5. B. BRAUN MELSUNGEN AG
  • 12.6. ASAHI KASEI MEDICAL CO., LTD. (A SUBSIDIARY OF ASAHI KASEI CORPORATION)
  • 12.7. BELLCO S.R.L. (A PART OF MEDTRONIC PLC)
  • 12.8. TORAY MEDICAL CO., LTD.
  • 12.9. INFOMED SA
  • 12.10. MEDICA S.P.A.
  • 12.11. MEDICAL COMPONENTS, INC.
  • 12.12. MEDITES PHARMA SPOL. S.R.O.
  • 12.13. MEDTRONIC PLC
  • 12.14. SWS HEMODIALYSIS CARE CO. LTD.
  • 12.15. NINGBO TIANYI MEDICAL APPLIANCE CO., LTD.

*Details on MarketsandMarkets view, Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, and Recent Developments might not be captured in case of unlisted companies.

13. APPENDIX

  • 13.1. INSIGHTS OF INDUSTRY EXPERTS
  • 13.2. DISCUSSION GUIDE
  • 13.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 13.5. AVAILABLE CUSTOMIZATIONS
  • 13.6. RELATED REPORTS
  • 13.7. AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: AVERAGE SELLING PRICE OF CRRT MACHINES, BY MANUFACTURER, 2016 (USD)
  • TABLE 2: AVERAGE SELLING PRICE OF CRRT BLOODLINES AND DIALYSATE BAGS, 2016 (USD)
  • TABLE 3: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2015-2022 (USD MILLION)
  • TABLE 4: CONTINUOUS RENAL REPLACEMENT THERAPY DIALYSATES & REPLACEMENT FLUIDS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 5: EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY DIALYSATES & REPLACEMENT FLUIDS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 6: NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY DIALYSATES & REPLACEMENT FLUIDS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 7: ASIA-PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY DIALYSATES & REPLACEMENT FLUIDS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 8: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 9: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 10: EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 11: NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 12: ASIA-PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 13: CONTINUOUS RENAL REPLACEMENT THERAPY SYSTEMS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 14: EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY SYSTEMS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 15: NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY SYSTEMS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 16: ASIA-PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY SYSTEMS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 17: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2015-2022 (USD MILLION)
  • TABLE 18: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR CVVH, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 19: EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR CVVH, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 20: NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR CVVH, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 21: ASIA-PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR CVVH, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 22: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR CVVHDF, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 23: EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR CVVHDF, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 24: NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR CVVHDF, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 25: ASIA-PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR CVVHDF, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 26: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR CVVHD, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 27: EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR CVVHD, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 28: NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR CVVHD, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 29: ASIA-PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR CVVHD, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 30: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR SCUF, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 31: EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR SCUF, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 32: NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR SCUF, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 33: ASIA-PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR SCUF, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 34: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 35: EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 36: EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2015-2022 (USD MILLION)
  • TABLE 37: EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2015-2022 (USD MILLION)
  • TABLE 38: GERMANY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 39: GERMANY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2015-2022 (USD MILLION)
  • TABLE 40: U.K.: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2015-2022 (USD MILLION)
  • TABLE 41: U.K.: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2015-2022 (USD MILLION)
  • TABLE 42: FRANCE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2015-2022 (USD MILLION)
  • TABLE 43: FRANCE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2015-2022 (USD MILLION)
  • TABLE 44: ROE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT, 2015-2022 (USD MILLION)
  • TABLE 45: ROE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, BY MODALITY, 2015-2022 (USD MILLION)
  • TABLE 46: NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 47: NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2015-2022 (USD MILLION)
  • TABLE 48: NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2015-2022 (USD MILLION)
  • TABLE 49: U.S.: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2015-2022 (USD MILLION)
  • TABLE 50: U.S.: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2015-2022 (USD MILLION)
  • TABLE 51: CANADA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2015-2022 (USD MILLION)
  • TABLE 52: CANADA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2015-2022 (USD MILLION)
  • TABLE 53: ASIA-PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 54: ASIA-PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2015-2022 (USD MILLION)
  • TABLE 55: ASIA-PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2015-2022 (USD MILLION)
  • TABLE 56: JAPAN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2015-2022 (USD MILLION)
  • TABLE 57: JAPAN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2015-2022 (USD MILLION)
  • TABLE 58: CHINA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2015-2022 (USD MILLION)
  • TABLE 59: CHINA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2015-2022 (USD MILLION)
  • TABLE 60: INDIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2015-2022 (USD MILLION)
  • TABLE 61: INDIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2015-2022 (USD MILLION)
  • TABLE 62: ROAPAC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2015-2022 (USD MILLION)
  • TABLE 63: ROAPAC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2015-2022 (USD MILLION)
  • TABLE 64: ROW: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2015-2022 (USD MILLION)
  • TABLE 65: ROW: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2015-2022 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1: GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: RESEARCH METHODOLOGY STEPS
  • FIGURE 2: RESEARCH DESIGN
  • FIGURE 3: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4: SUPPLY SIDE
  • FIGURE 5: DEMAND SIDE
  • FIGURE 6: ESTIMATION OF CRRT PROCEDURAL VOLUME
  • FIGURE 7: RESEARCH METHODOLOGY: TOP-DOWN APPROACH [FOR MARKET SIZE ESTIMATION OF DISPOSABLES (BLOODLINE SETS, HEMOFILTERS, AND OTHER DISPOSABLES)]
  • FIGURE 8: RESEARCH METHODOLOGY: TOP-DOWN APPROACH (FOR MARKET SIZE ESTIMATION OF CRRT SYSTEMS)
  • FIGURE 9: RESEARCH METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 10: DATA TRIANGULATION STEPS (TOP-DOWN AND BOTTOM-UP APPROACHES)
  • FIGURE 11: DATA TRIANGULATION METHODOLOGY
  • FIGURE 12: GLOBAL CRRT MARKET BY PRODUCT, 2017 VS. 2022
  • FIGURE 13: HEMOFILTERS TO FORM THE LARGEST SEGMENT OF CRRT DISPOSABLES MARKET IN 2017
  • FIGURE 14: CVVHDF EXPECTED TO BE THE FASTEST-GROWING SEGMENT DURING 2017-2022
  • FIGURE 15: ASIA-PACIFIC TO GROW AT THE HIGHEST GROWTH RATE IN THE FORECAST PERIOD
  • FIGURE 16: RISING PREVALENCE OF AKI TO DRIVE THE GLOBAL CRRT MARKET DURING THE FORECAST PERIOD
  • FIGURE 17: DIALYSATES & REPLACEMENT FLUIDS TO DOMINATE THE GLOBAL CRRT MARKET DURING THE FORECAST PERIOD
  • FIGURE 18: EUROPE TO DOMINATE CRRT MODALITY SEGMENTS IN 2017
  • FIGURE 19: EUROPE TO DOMINATE THE GLOBAL CRRT MARKET DURING THE FORECAST PERIOD
  • FIGURE 20: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 21: GLOBAL INCIDENCE OF ACUTE KIDNEY INJURY (AKI), 2010 VS. 2015 VS. 2020
  • FIGURE 22: KEY FACTORS AFFECTING THE REIMBURSEMENT RATES FOR CRRT PROCEDURES
  • FIGURE 23: REIMBURSEMENT SCENARIO FOR CRRT (AS OF 2016)
  • FIGURE 24: REIMBURSEMENT STRUCTURES IN EUROPE
  • FIGURE 25: KEY REGULATORY BODIES INVOLVED IN THE APPROVAL OF NEW CRRT PRODUCTS
  • FIGURE 26: PORTER'S FIVE FORCES ANALYSIS - GLOBAL CRRT MARKET
  • FIGURE 27: DESIGN RECOMMENDATIONS FOR CRRT MACHINES
  • FIGURE 28: UTILIZATION OF CONTINUOUS RENAL REPLACEMENT THERAPY AND DIALYSIS FOR THE TREATMENT OF RENAL PATIENTS IN ICUS, BY REGION (2016)
  • FIGURE 29: RATE OF SWITCHING FROM CRRT TO IHD, BY REGION, 2016
  • FIGURE 30: NUMBER OF CRRT PATIENTS ACROSS THE GLOBE, 2016
  • FIGURE 31: GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT (2017 VS. 2022)
  • FIGURE 32: TYPES OF CRRT MODALITIES
  • FIGURE 33: GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY (2017 VS. 2022)
  • FIGURE 34: EUROPE TO DOMINATE THE GLOBAL CRRT MARKET DURING THE FORECAST PERIOD
  • FIGURE 35: EUROPE: CRRT MARKET SNAPSHOT
  • FIGURE 36: NORTH AMERICA: CRRT MARKET SNAPSHOT
  • FIGURE 37: ASIA-PACIFIC: CRRT MARKET SNAPSHOT
  • FIGURE 38: ROW: CRRT MARKET SNAPSHOT
  • FIGURE 39: COMPETITIVE LEADERSHIP MAPPING
  • FIGURE 40: GLOBAL CRRT MARKET SHARE, BY KEY PLAYERS (2016)
  • FIGURE 41: SCORING METHODOLOGY
  • FIGURE 42: COMPARISON OF COMPETITIVE INTENSITY SCORES
  • FIGURE 43: RELATIVE POSITIONING OF COMPANIES BASED ON COMPETITIVE INTENSITY SCORE AND CRRT FOCUS
  • FIGURE 44: BAXTER INTERNATIONAL INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 45: FRESENIUS MEDICAL CARE AG & CO. KGAA: COMPANY SNAPSHOT (2016)
  • FIGURE 46: NIKKISO CO., LTD.: COMPANY SNAPSHOT (2015)
  • FIGURE 47: NXSTAGE MEDICAL, INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 48: B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT (2016)
  • FIGURE 49: ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2015)
  • FIGURE 50: TORAY INDUSTRIES, INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 51: MEDTRONIC PLC.: COMPANY SNAPSHOT (2016)
Back to Top